Navigation Links
Circulating tumor cells correlate with poorer survival in pancreatic cancer patients
Date:5/28/2010

CHICAGO, IL. (May 28, 2010)Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor cells. Additionally, the team has uncovered evidence that not all circulating tumor cells are the same, and some may predict worse outcomes than others.

Benjamin P. Negin, M.D., a medical oncology fellow at Fox Chase, will present the study at the 46th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 6.

"Eventually, we hope we can use changes in number of circulating tumor cells to make real-time treatment decisions, instead of having to wait weeks for radiological scans," says Negin. "This is one of the first studies looking at the role of circulating tumor cells in pancreatic cancer."

Previous work has demonstrated that prostate, colon, or breast cancer patients who have more circulating tumor cells have poorer survival than patients with fewer circulating tumor cells. To learn whether a similar scenario occurs in pancreatic cancer patients, Negin and colleagues enrolled 48 patients with pancreatic cancer in the current study (additional patients still being added).

The team used an immunomagnetic separation system to isolate circulating tumor cells from patients' blood at three time points. The time points included study entry, seven days after the start of therapy, and at the time of their first radiological evaluation, which was six to ten weeks after initiating therapy.

The team found that 50% of the patients had one or more circulating tumor cell per 7.5 mL peripheral blood at baseline. That proportion decreased to 40% after seven days of therapy and to 32% at the time of the first scan.

In addition, the presence of circulating tumor cells correlated with patient outcomes. Patients with circulating tumor cells at study entry had a median overall survival of 191 days compared with 269 days for those without circulating tumor cells, although the difference did not reach statistical significance in the small study population. A similar trend appeared for progression-free survival, with a median of 85 days for those with detectable circulating tumor cells compared with 137 days for those without.

Patients who had circulating tumor cells at either point after therapy initiation also trended towards poorer overall or progression-free survival.

Interestingly, the investigators found that some circulating tumor cells may be worse than others. Patients whose circulating tumor cells expressed the MUC1 protein, which has been associated with more aggressive pancreatic cancer, trended towards a shorter median overall survival than those whose circulating tumor cells did not express the protein, at 85.5 and 310 days, respectively.

"We find that having circulating tumor cells is bad," Negin says. "But the more interesting story that appears to be coming out of our study is that not all circulating tumor cells are equal. The MUC1 cells seem particularly bad, suggesting that there is a difference in the biology of these tumors and providing some insight into how these tumors function."


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Survival in metastatic breast cancer directly linked to circulating tumor cells
2. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
3. Revisiting the need to detect circulating tumor cells
4. Novel detection method unmasks circulating breast cancer cells
5. Single Lung Tumor Contains 50,000 Mutations
6. Single Lung Tumor Contains 50,000 Mutated Genes
7. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
8. A new cancer vaccine starves tumors of blood
9. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
10. Oncolytic viruses mediating anti-tumor immunity in human cancer patients
11. Genetics of childrens brain tumor unlocked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks ... Amica Insurance is sharing tips to make sure your family and vehicle are ... National Safety Council, there may be 439 deaths and an additional 50,500 serious injuries ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: